H.C. Wainwright analyst Douglas Tsao has reiterated their bullish stance on APLS stock, giving a Buy rating yesterday.
Douglas Tsao has given his Buy rating due to a combination of factors that highlight Apellis Pharmaceuticals’ potential for growth despite recent challenges. The company’s product, Syfovre, experienced a decline in sales in the first quarter of 2025, falling short of market expectations. However, this was largely due to temporary issues such as inventory drawdowns and increased reliance on samples due to funding shortages at co-pay assistance foundations.
Despite these setbacks, the demand for Syfovre remains strong, as evidenced by the increase in physician orders and the significant number of doses delivered. The company’s proactive approach in engaging with patients and doctors through its patient assistance program is expected to mitigate financial burdens and sustain demand. Additionally, Syfovre’s dosing schedule offers a competitive advantage by reducing annual costs for patients, which is likely to support its market leadership. Tsao remains optimistic about Syfovre’s potential to become a blockbuster product, although he acknowledges that achieving this status may take longer than initially anticipated.
According to TipRanks, Tsao is a 5-star analyst with an average return of 9.9% and a 40.45% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Evolus, and Neumora Therapeutics, Inc..
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $29.00 price target.